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Summary
The Centers for Disease Control and Prevention (CDC) continues to work closely with state 
public health departments on a multistate investigation of fungal meningitis and other infections 
among patients who received a methylprednisolone acetate (MPA) injection prepared by the 
New England Compounding Center (NECC) in Framingham, Mass. This HAN notice provides 
updated information on the following:
• Epidural abscess and other clinical syndromes being diagnosed in exposed patients
• Diagnostic and treatment recommendations for clinicians
Background
As of November 19, 2012, a total of 490 cases, which includes 34 deaths, have been reported in 
19 states (see CDC's website for up-to-date information about case count and distribution by 
state). Exserohilum rostratum continues to be the predominant fungus identified in patients and 
confirmed by the CDC laboratory.
Clinical Syndromes Reported to CDC
Currently, more than 7 weeks after the three implicated lots of MPA1 were recalled, CDC 
continues to receive reports of fungal infection in exposed patients. Previously, the majority of 
new cases reported to CDC were patients with fungal meningitis following injection.
Although cases of fungal meningitis continue to be reported, CDC has recently observed an 
increase in the number of patients presenting with evidence of epidural abscess, phlegmon,
discitis, vertebral osteomyelitis, or arachnoiditis at or near the site of injection. These 
complications have occurred in patients with and without evidence of fungal meningitis.
Of the 91 cases reported to CDC since November 4, 2012, a total of 26 (29%) were classified as 
meningitis, 61 (67%) had spinal or paraspinal epidural abscess or osteomyelitis, 2 (2%) had 
peripheral joint infection, and 2 (2%) had more than one condition(Figure 1).
Figure 1
Note: Data presented in Figure 1 are preliminary and subject to change. Additional patients may 
ultimately meet multiple case definitions (e.g., meningitis and osteomyelitis/abscess) as more 
time elapses and additional information is provided to CDC. Reporting dates to CDC may lag 
behind onset dates.
Diagnostic and Treatment Guidance
As a reminder, CDC’s current diagnostic and treatment guidance addresses management of 
patients with epidural abscess or other complications at or near the injection site. These localized 
infections may occur in isolation or in patients previously diagnosed with fungal meningitis. 
Although patients with these localized infections frequently have new or worsening back pain, 
symptoms may be mild or clinically difficult to distinguish from the patient’s baseline chronic 
pain. Based on current information, CDC recommends the following diagnostic protocol:
• In patients with new or worsening symptoms at or near the injection site, physicians should 
obtain an MRI with contrast of the symptomatic area(s), if not contraindicated. This 
recommendation also applies to patients being treated for meningitis. In some cases, radiologic 
evidence of abscess or phlegmon has become apparent on repeat MRI studies performed 
subsequent to an initially normal imaging procedure. Clinicians should therefore have a low 
threshold for repeat MRI studies in patients who continue to have symptoms localizing to the 
site of injection, even after a normal study. However, the optimal duration between MRI 
studies is unknown.
• CDC has received reports of patients being treated for fungal meningitis who had no previous 
evidence of localized infection at the site of injection, but who were subsequently found to 
have evidence of localized infection (e.g., epidural abscess, phlegmon, discitis, vertebral 
osteomyelitis, or arachnoiditis) on imaging studies. Therefore, in patients being treated for 
meningitis, even in the absence of new or worsening symptoms at or near the injection site, 
clinicians should strongly consider obtaining an MRI of the injection site approximately 2-3 
weeks after diagnosis of meningitis. Early identification of new disease may facilitate 
additional specific interventions (e.g., drainage) and provide information for measuring 
effectiveness of therapy thereafter.
• For patients demonstrated to have epidural abscess, phlegmon, discitis, vertebral osteomyelitis, 
or arachnoiditis, early consultation with a neurosurgeon to discuss whether surgical 
management, including debridement, is warranted in addition to antifungal therapy (for 
information about antifungal therapy, see Interim Treatment Guidance for Central Nervous 
System and Parameningeal Infections Associated with Injection of Contaminated Steroid 
Products http://www.cdc.gov/hai/outbreaks/clinicians/guidance cns.html).
CDC continues to gather data from existing and newly reported cases of infection and will use 
this information to inform updates to existing guidance. Healthcare professionals with patients
under their care should check CDC's website for the most up-to-date clinical guidance because 
information is subject to change.
NECC lots of methylprednisolone acetate (PF) 80mg/ml:
Methylprednisolone Acetate (PF) 80 mg/ml Injection, Lot #05212012@68, BUD 11/17/2012 
Methylprednisolone Acetate (PF) 80 mg/ml Injection, Lot #06292012@26, BUD 12/26/2012 
Methylprednisolone Acetate (PF) 80 mg/ml Injection, Lot #08102012@51, BUD 2/6/2013
The Centers for Disease Control and Prevention (CDC) protects people's health and safety by 
preventing and controlling diseases and injuries; enhances health decisions by providing 
credible information on critical health issues; and promotes healthy living through strong 
partnerships with local, national and international organizations.
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